{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T00:37:40Z","timestamp":1775695060756,"version":"3.50.1"},"reference-count":46,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>BACKGROUND<\/jats:title>\n                  <jats:p>Prostate cancer (PCa) remains the most common solid malignancy in men, and its prevalence makes understanding its heritability of paramount importance. To date, the most common factors used to estimate a man's risk of developing PCa are age, race, and family history. Despite recent advances in its utility in multiple malignancies (e.g., breast and colon cancer), genetic testing is still relatively underutilized in PCa.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>CONTENT<\/jats:title>\n                  <jats:p>Multiple highly penetrant genes (HPGs) and single-nucleotide polymorphisms (SNPs) have been show to increase a patient's risk of developing PCa. Mutations in the former, like DNA damage repair genes, can confer a 2- to 3-fold increased risk of developing PCa and can increase the risk of aggressive disease. Similarly, PCa-risk SNPs can be used to create risk scores (e.g., genetic or polygenic risk scores) that can be used to further stratify an individual's disease susceptibility. Specifically, these genetic risk scores can provide more specific estimates of a man's lifetime risk ranging up to &amp;gt;6-fold higher risk of PCa.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>SUMMARY<\/jats:title>\n                  <jats:p>It is becoming increasingly evident that in addition to the standard family history and race information, it is necessary to obtain genetic testing (including an assessment of HPG mutation status and genetic risk score) to provide a full risk assessment. The additional information derived thereby will improve current practices in PCa screening by risk-stratifying patients before initial prostate-specific antigen testing, determining a patient's frequency of visits, and even help identify potentially at-risk family members.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1373\/clinchem.2018.286658","type":"journal-article","created":{"date-parts":[[2018,11,20]],"date-time":"2018-11-20T17:51:56Z","timestamp":1542736316000},"page":"74-79","source":"Crossref","is-referenced-by-count":20,"title":["Germline Genetics of Prostate Cancer: Time to Incorporate Genetics into Early Detection Tools"],"prefix":"10.1093","volume":"65","author":[{"given":"Richard J","family":"Fantus","sequence":"first","affiliation":[{"name":"Section of Urology, Department of Surgery, University of Chicago Medicine, Chicago, IL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian T","family":"Helfand","sequence":"first","affiliation":[{"name":"Division of Urology, Department of Surgery, NorthShore University Health System, Evanston, IL"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2019,1,1]]},"reference":[{"key":"2020022605525588300_B1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21442","article-title":"Cancer statistics, 2018","volume":"68","author":"Siegel","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"2020022605525588300_B2","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1210\/edrv.20.1.0356","article-title":"Molecular genetics and epidemiology of prostate carcinoma","volume":"20","author":"Ruijter","year":"1999","journal-title":"Endocr Rev"},{"key":"2020022605525588300_B3","unstructured":"NIH. Genetics of prostate cancer (PDQ\u00ae)\u2014health professional version. April2018. https:\/\/www.cancer.gov\/types\/prostate\/hp\/prostate-genetics-pdq#link\/_1051 (Accessed April 2018)."},{"key":"2020022605525588300_B4","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/nrurol.2014.91","article-title":"Prostate cancer in young men: an important clinical entity","volume":"11","author":"Salinas","year":"2014","journal-title":"Nat Rev Urol"},{"key":"2020022605525588300_B5","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1001\/jama.1995.03530200035033","article-title":"Race, treatment, and long-term survival from prostate cancer in an equal-access medical care delivery system","volume":"274","author":"Optenberg","year":"1995","journal-title":"JAMA"},{"key":"2020022605525588300_B6","doi-asserted-by":"crossref","first-page":"e27130","DOI":"10.1371\/journal.pone.0027130","article-title":"An epidemiological reappraisal of the familial aggregation of prostate cancer: a meta-analysis","volume":"6","author":"Kici\u0144ski","year":"2011","journal-title":"PLoS One"},{"key":"2020022605525588300_B7","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1158\/1055-9965.EPI-13-0568","article-title":"The heritability of prostate cancer in the Nordic Twin Study of Cancer","volume":"23","author":"Hjelmborg","year":"2014","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"2020022605525588300_B8","doi-asserted-by":"crossref","first-page":"3367","DOI":"10.1073\/pnas.89.8.3367","article-title":"Mendelian inheritance of familial prostate cancer","volume":"89","author":"Carter","year":"1992","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2020022605525588300_B9","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1002\/(SICI)1097-0215(19970317)70:6<679::AID-IJC9>3.0.CO;2-S","article-title":"Family history of prostate cancer: a multi-center case-control study in Canada","volume":"70","author":"Ghadirian","year":"1997","journal-title":"Int J Cancer"},{"key":"2020022605525588300_B10","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S0090-4295(00)00891-8","article-title":"Autosomal dominant inheritance of prostate cancer: a confirmatory study","volume":"57","author":"Verhage","year":"2001","journal-title":"Urology"},{"key":"2020022605525588300_B11","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1002\/(SICI)1097-0045(19971201)33:4<240::AID-PROS3>3.0.CO;2-L","article-title":"Heredity and prostate cancer: a study of World War II veteran twins","volume":"33","author":"Page","year":"1997","journal-title":"The Prostate"},{"key":"2020022605525588300_B12","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1086\/301862","article-title":"Evidence for autosomal dominant inheritance of prostate cancer","volume":"62","author":"Schaid","year":"1998","journal-title":"Am J Hum Genet"},{"key":"2020022605525588300_B13","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1023\/A:1015755219674","article-title":"Segregation analysis of prostate cancer in 1,719 white, African-American and Asian-American families in the United States and Canada","volume":"13","author":"Gong","year":"2002","journal-title":"Cancer Causes Control CCC"},{"key":"2020022605525588300_B14","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1093\/oxfordjournals.aje.a009313","article-title":"Segregation analysis of prostate cancer in Sweden: support for dominant inheritance","volume":"146","author":"Gr\u00f6nberg","year":"1997","journal-title":"Am J Epidemiol"},{"key":"2020022605525588300_B15","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/sj.pcan.4500279","article-title":"Genetic predisposition to prostate cancer","volume":"2","author":"Eeles","year":"1999","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"2020022605525588300_B16","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1038\/ng.882","article-title":"Seven prostate cancer susceptibility loci identified by a multi-stage genome-wide association study","volume":"43","author":"Kote-Jarai","year":"2011","journal-title":"Nat Genet"},{"key":"2020022605525588300_B17","doi-asserted-by":"crossref","first-page":"520","DOI":"10.4103\/1008-682X.179527","article-title":"Population-standardized genetic risk score: the SNP-based method of choice for inherited risk assessment of prostate cancer","volume":"18","author":"Conran","year":"2016","journal-title":"Asian J Androl"},{"key":"2020022605525588300_B18","doi-asserted-by":"crossref","first-page":"509","DOI":"10.4103\/1008-682X.182981","article-title":"Clinical validity and utility of genetic risk scores in prostate cancer","volume":"18","author":"Helfand","year":"2016","journal-title":"Asian J Androl"},{"key":"2020022605525588300_B19","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/j.cell.2015.05.001","article-title":"Integrative clinical genomics of advanced prostate cancer","volume":"161","author":"Robinson","year":"2015","journal-title":"Cell"},{"key":"2020022605525588300_B20","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.eururo.2016.11.033","article-title":"Germline mutations in ATM and BRCA1\/2 distinguish risk for lethal and indolent prostate cancer and are associated with early age at death","volume":"71","author":"Na","year":"2017","journal-title":"Eur Urol"},{"key":"2020022605525588300_B21","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1093\/jnci\/94.18.1358","article-title":"Cancer incidence in BRCA1 mutation carriers","volume":"94","author":"Thompson","year":"2002","journal-title":"J Natl Cancer Inst"},{"key":"2020022605525588300_B22","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1200\/JCO.2004.05.055","article-title":"Cancer risks for male carriers of germline mutations in BRCA1 or BRCA2: a review of the literature","volume":"22","author":"Liede","year":"2004","journal-title":"J Clin Oncol"},{"key":"2020022605525588300_B23","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1002\/cncr.29041","article-title":"Cancers associated with BRCA1 and BRCA2 mutations other than breast and ovarian","volume":"121","author":"Mersch","year":"2015","journal-title":"Cancer"},{"key":"2020022605525588300_B24","doi-asserted-by":"crossref","first-page":"13671","DOI":"10.1038\/ncomms13671","article-title":"Germline BRCA2 mutations drive prostate cancers with distinct evolutionary trajectories","volume":"8","author":"Taylor","year":"2017","journal-title":"Nat Commun"},{"key":"2020022605525588300_B25","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1038\/sj.bjc.6604453","article-title":"Rapid progression of prostate cancer in men with a BRCA2 mutation","volume":"99","author":"Narod","year":"2008","journal-title":"Br J Cancer"},{"key":"2020022605525588300_B26","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1158\/1055-9965.EPI-08-0556","article-title":"The role of the BRCA2 gene in susceptibility to prostate cancer revisited","volume":"17","author":"Ostrander","year":"2008","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"2020022605525588300_B27","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1056\/NEJMoa1603144","article-title":"Inherited DNA-repair gene mutations in men with metastatic prostate cancer","volume":"375","author":"Pritchard","year":"2016","journal-title":"N Engl J Med"},{"key":"2020022605525588300_B28","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.cancergencyto.2010.02.014","article-title":"Association between polymorphisms of TP53 and MDM2 and prostate cancer risk in southern Chinese","volume":"202","author":"Xu","year":"2010","journal-title":"Cancer Genet Cytogenet"},{"key":"2020022605525588300_B29","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.arcmed.2011.03.001","article-title":"Role of functional polymorphisms of P53 and P73 genes with the risk of prostate cancer in a case-control study from Northern India","volume":"42","author":"Mittal","year":"2011","journal-title":"Arch Med Res"},{"key":"2020022605525588300_B30","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1158\/1055-9965.EPI-05-0910","article-title":"Role of the Nijmegen breakage syndrome 1 gene in familial and sporadic prostate cancer","volume":"15","author":"Hebbring","year":"2006","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"2020022605525588300_B31","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1056\/NEJMoa1110000","article-title":"Germline mutations in HOXB13 and prostate-cancer risk","volume":"366","author":"Ewing","year":"2012","journal-title":"N Engl J Med"},{"key":"2020022605525588300_B32","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s00439-012-1229-4","article-title":"HOXB13 is a susceptibility gene for prostate cancer: results from the International Consortium for Prostate Cancer Genetics (ICPCG)","volume":"132","author":"Xu","year":"2013","journal-title":"Hum Genet"},{"key":"2020022605525588300_B33","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.eururo.2013.03.007","article-title":"Germline homeobox B13 (HOXB13) G84E mutation and prostate cancer risk in European descendants: a meta-analysis of 24,213 cases and 73,631 controls","volume":"64","author":"Shang","year":"2013","journal-title":"Eur Urol"},{"key":"2020022605525588300_B34","doi-asserted-by":"crossref","first-page":"2568","DOI":"10.1200\/JCO.2016.71.9260","article-title":"Multigene panel testing provides a new perspective on Lynch syndrome","volume":"35","author":"Espenschied","year":"2017","journal-title":"J Clin Oncol"},{"key":"2020022605525588300_B35","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1200\/JCO.2012.44.1238","article-title":"Elevated risk of prostate cancer among men with Lynch syndrome","volume":"31","author":"Raymond","year":"2013","journal-title":"J Clin Oncol"},{"key":"2020022605525588300_B36","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1158\/1055-9965.EPI-13-1165","article-title":"Risk of prostate cancer in Lynch syndrome: a systematic review and meta-analysis","volume":"23","author":"Ryan","year":"2014","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"2020022605525588300_B37","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/s10689-014-9744-1","article-title":"High prevalence of mismatch repair deficiency in prostate cancers diagnosed in mismatch repair gene mutation carriers from the colon cancer family registry","volume":"13","author":"Rosty","year":"2014","journal-title":"Fam Cancer"},{"key":"2020022605525588300_B38","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s10689-012-9591-x","article-title":"EPCAM deletion carriers constitute a unique subgroup of Lynch syndrome patients","volume":"12","author":"Ligtenberg","year":"2013","journal-title":"Fam Cancer"},{"key":"2020022605525588300_B39","doi-asserted-by":"crossref","first-page":"620","DOI":"10.6004\/jnccn.2018.0036","article-title":"NCCN guidelines updates: prostate cancer and prostate cancer early detection","volume":"16","author":"Carroll","year":"2018","journal-title":"J Natl Compr Cancer Netw"},{"key":"2020022605525588300_B40","doi-asserted-by":"publisher","DOI":"10.1200\/PO.17.00029","article-title":"Prospective genomic profiling of prostate cancer across disease states reveals germline and somatic alterations that may affect clinical decision making","author":"Abida","year":"2017","journal-title":"JCO Precis Oncol"},{"key":"2020022605525588300_B41","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1038\/s41588-018-0142-8","article-title":"Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci","volume":"50","author":"Schumacher","year":"2018","journal-title":"Nat Genet"},{"key":"2020022605525588300_B42","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/gim.2015.125","article-title":"Multigene panels in prostate cancer risk assessment: a systematic review","volume":"18","author":"Little","year":"2016","journal-title":"Genet Med"},{"key":"2020022605525588300_B43","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1002\/pros.23200","article-title":"Adding genetic risk score to family history identifies twice as many high-risk men for prostate cancer: results from the prostate cancer prevention trial","volume":"76","author":"Chen","year":"2016","journal-title":"The Prostate"},{"key":"2020022605525588300_B44","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.eururo.2017.12.028","article-title":"The Stockholm-3 model for prostate cancer detection: algorithm update, biomarker contribution, and reflex test potential","volume":"74","author":"Str\u00f6m","year":"2018","journal-title":"Eur Urol"},{"key":"2020022605525588300_B45","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1002\/pros.23369","article-title":"Reclassification of prostate cancer risk using sequentially identified SNPs: results from the REDUCE trial","volume":"77","author":"Chen","year":"2017","journal-title":"The Prostate"},{"key":"2020022605525588300_B46","doi-asserted-by":"crossref","first-page":"505","DOI":"10.4103\/1008-682X.179529","article-title":"Personalized prostate cancer care: from screening to treatment","volume":"18","author":"Conran","year":"2016","journal-title":"Asian J Androl"}],"container-title":["Clinical Chemistry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/clinchem\/article-pdf\/65\/1\/74\/32638533\/clinchem0074.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/clinchem\/article-pdf\/65\/1\/74\/32638533\/clinchem0074.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,26]],"date-time":"2020-02-26T10:57:50Z","timestamp":1582714670000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/clinchem\/article\/65\/1\/74\/5607905"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,1]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,1,1]]},"published-print":{"date-parts":[[2019,1,1]]}},"URL":"https:\/\/doi.org\/10.1373\/clinchem.2018.286658","relation":{},"ISSN":["0009-9147","1530-8561"],"issn-type":[{"value":"0009-9147","type":"print"},{"value":"1530-8561","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,1,1]]},"published":{"date-parts":[[2019,1,1]]}}}